Acute Low Back Pain – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2024 To 2034
Acute Low Back Pain Market Outlook
Thelansis’s “Acute Low Back Pain
Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report
– 2024 To 2034" covers disease overview, epidemiology, drug utilization,
prescription share analysis, competitive landscape, clinical practice,
regulatory landscape, patient share, market uptake, market forecast, and key
market insights under the potential Acute Low Back Pain treatment modalities
options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan,
and China).
Acute Low
Back Pain Overview
Acute Low
back pain is pain, muscle tension, or stiffness, localised below the costal
margin and above the inferior gluteal folds, with or without referred or
radicular leg pain persists for <12 weeks. Acute LBP may be self-limiting,
although there is a high recurrence rate with less-painful symptoms recurring
in 50% to 80% of people within one year of the initial episode; 1 year later,
as many as 33% of people still experience moderate-intensity pain and 15%
experience severe pain. This type of pain is most common between the ages of 35
to 55 years. Symptoms, pathology, and radiological appearances are poorly
correlated. An anatomical source of the pain cannot be identified in about 80%
of people. Acute LBP is the 2nd most common symptomatic reason for office
visits to primary care physicians and the most common sense for office visits
to orthopaedic surgeons, neurosurgeons, and occupational medicine physicians.
Recurrence of LBP is common; 60-80% of patients experience recurrence within
two years.
Geography
coverage:
G8 (United States,
EU5 [France, Germany, Italy, Spain, U.K.], Japan, and China)
Insights driven
by robust research, including:
- In-depth interviews with leading
KOLs and payers
- Physician surveys
- RWE analysis for claims and EHR
datasets
- Secondary research (e.g.,
peer-reviewed journal articles, third-party research databases)
Deliverables
format and updates*:
- Detailed Report (PDF)
- Market Forecast Model (MS
Excel-based automated dashboard)
- Epidemiology (MS Excel; interactive
tool)
- Executive Insights (PowerPoint
presentation)
- Others: regular updates,
customizations, consultant support
*As per
Thelansis’s policy, we ensure that we include all the recent updates before
releasing the report content and market model.
Salient
features of Market Forecast model:
- 10-year market forecast (2024–2034)
- Bottom-up patient-based market
forecasts validated through the top-down sales methodology
- Covers clinically and
commercially-relevant patient populations/ line of therapies
- Annualized drug-level sales and
patient share projections
- Utilizes our proprietary Epilansis and Analog tool
(e.g., drug uptake and erosion) datasets and conjoint analysis approach
- Detailed methodology/sources
& assumptions
- Graphical and tabular outputs
- Users can customize the model based
on requirements
Key business
questions answered:
- How can drug development and
lifecycle management strategies be optimized across G8 markets (US, EU5,
Japan, and China)?
- How large is the patient population
in terms of incidence, prevalence, segments, and those receiving drug
treatments?
- What is the 10-year market outlook
for sales and patient share?
- Which events will have the greatest
impact on the market’s trajectory?
- What insights do interviewed experts
provide on current and emerging treatments?
- Which pipeline products show the
most promise, and what is their potential for launch and future
positioning?
- What are the key unmet needs and KOL
expectations for target profiles?
- What key regulatory and payer
requirements must be met to secure drug approval and favorable market
access?
- and more…
Comments
Post a Comment